F9
Coagulation factor IX
Also known as: FA9_HUMAN, FIX
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P00740
- Gene
- F9
- Ensembl
- ENSG00000101981
- Chromosome
- X
- Canonical length
- 461 aa
- Protein class
- Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Sep 2015]
Canonical amino-acid sequenceUniProt
461 residues, UniProt reviewed canonical sequence.
>P00740|F9
1 MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL
61 ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP
121 FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR
181 VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW
241 QVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII
301 PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF
361 HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE
421 GTSFLTGIIS WGEECAMKGK YGIYTKVSRY VNWIKEKTKL TLocalizationUniProt · AlphaFold · HPA
Whether an antibody against F9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 659 nTPM
Expression across tissuesHPA
Tissue
- liver: 659 nTPM
- spleen: 0.2 nTPM
- kidney: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
Single-cell type
- hepatocytes: 677 nCPM
- hepatic stellate cells: 6.5 nCPM
- kupffer cells: 4.1 nCPM
- cholangiocytes: 2.7 nCPM
- megakaryocyte progenitors: 1 nCPM
- thymocytes: 0.8 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about F9.
Disease | AllUniProt
Conditions F9 is implicated in, by any mechanism.
- Hemophilia B (HEMB) MIM:306900
- Thrombophilia, X-linked, due to factor IX defect (THPH8) MIM:300807
- Warfarin sensitivity, X-linked (WARFS) MIM:301052
Disease | GeneticClinVar
313 pathogenic / likely-pathogenic of 681 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hereditary factor IX deficiency disease
- Thrombophilia, X-linked, due to factor 9 defect
- Hereditary factor VIII deficiency disease
- F9-related disorder
- Warfarin sensitivity, X-linked
Disease | AutoantibodyPubMed
Conditions in which antibodies against F9 are reported. Each links to that disease's full target list.
Showing 0 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for F9 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
13 publications
- Gene deletions in patients with haemophilia B and anti-factor IX antibodies.
1983 · Nature · RCR 5.5 · 199 citations - Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
2005 · Haemophilia · RCR 2.4 · 64 citations - Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia b and antibodies.
1983 · Scand J Haematol · RCR 2.3 · 49 citations - Immune tolerance in haemophilia: the long journey to the fork in the road.
2012 · Br J Haematol · RCR 1.7 · 55 citations - FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.
2014 · Blood · RCR 1.2 · 31 citations
Show 8 more
- Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.
2000 · Blood · RCR 1.2 · 54 citations - Humoral and cellular immunity to an encoded protein induced by direct DNA injection.
1994 · Hum Gene Ther · RCR 1.1 · 48 citations - DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene.
1990 · J Lab Clin Med · RCR 0.6 · 23 citations - Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
2009 · J Immunol · RCR 0.6 · 21 citations - Characterisation of the tolerant state in a patient with haemophilia B after removal of high-titre factor IX antibodies.
1985 · Scand J Haematol · RCR 0.4 · 8 citations - Epitope mapping of human factor IX inhibitor antibodies.
1994 · Br J Haematol · RCR 0.2 · 7 citations - Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report.
2016 · Biochem Med (Zagreb) · RCR 0.2 · 3 citations - Inhibitors to factor IX contain all IgG subclasses except IgG3.
1990 · Folia Haematol Int Mag Klin Morphol Blutforsch · RCR 0 · 1 citations
Reference: B cellIEDB
2 publications
- Epitope mapping of human factor IX inhibitor antibodies.
1994 · Br J Haematol · RCR 0.2 · 7 citations - Change of antigenic and neutralizing specificity in substitutional epitope peptides of hemophilia B inhibitor.
1998 · Peptides · RCR 0.1 · 5 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.17
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.18
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-type aspartate/asparagine hydroxylation site
- Gamma-carboxyglutamic acid-rich (GLA) domain
- EGF-like domain
- Serine proteases, trypsin domain
- Peptidase S1A, chymotrypsin family
- EGF-like calcium-binding domain
- Peptidase S1, PA clan
- Peptidase S1A, coagulation factor VII/IX/X/C/Z
- Coagulation factor-like, Gla domain superfamily
- EGF-like calcium-binding, conserved site
- Serine proteases, trypsin family, histidine active site
- Serine proteases, trypsin family, serine active site
- Gamma-carboxyglutamic acid-rich (GLA) domain superfamily
- Peptidase S1 family, coagulation factors
- EGF-like domain
- Trypsin
- Vitamin K-dependent carboxylation/gamma-carboxyglutamic (GLA) domain
- Coagulation Factor Xa inhibitory site
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of F9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads F9 as an antibody target. Whether an autoantibody or antibody against F9 could matter depends on whether native F9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
F9 is annotated as secreted, so native F9 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label F9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...